Akthelia Pharmaceuticals

About:

Late preclinical-stage immunotherapy biopharma company, with a breakthrough strategy to up-regulate the innate immunology of epithelia.

Website: http://www.aktheliapharma.com

Top Investors: Horizon Europe, Technology Development Fund

Description:

Akthelia is an emerging pharmaceutical company focused on the discovery and development of novel antimicrobial therapeutics, which enhance the body‘s innate microbial defences. The ever-increasing resistance to currently marketed antibiotics has led to a clear need for novel anti-infective agents that are active against drug resistant bacteria, opportunistic infections and acute infections of unknown causes. Akthelia has a diverse pipeline of products under development, targeting microbial infections. The current focus is on lung and gastrointestinal infections. In close collaboration with scientists at the Karolinska Institute in Stockholm and University of Iceland, evidence of new active ingredients and modes of action is being generated. The ensuing research is feeding the product pipeline and generating new product opportunities for further development.